A method for the treatment of diseases and disorders associated with the activity of β-like protein 1 transduction (TBL1), including myeloid proliferative neoplasia and chronic myeloid leukemia

摘要

The present invention relates to the use of the dioxim compound of anthracene-9,10-dione: dioxime 2 - ((3R, 5S) -3,5-dimethylpiperidin-1-ylsulfonyl) -7 - ((3S, 5R) -3,5-dimethylpiperidine -1-ylsulfonyl) anthracene-9,10-dione, for the treatment of malignant neoplasms, including myeloproliferative neoplasia, chronic myeloid leukemia and acute myeloid leukemia. Such a dioxime compound of anthracene-9,10-dione interrupts the Wnt / β-catenin pathway and inhibits the deregulated activity of this pathway, which acts in the direction of treatment, diagnosis and prevention of disorders associated with beta-catenin metabolism, as well as inhibits the interaction of transducine beta-like protein 1 (TBL1) with a beta-catenin coactivator molecule.